---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-062739"
form_type: "8-K"
ticker: "LITS"
cik: "0001262104"
company_name: "Lite Strategy, Inc."
filed_at: "2024-05-21T23:59:59+00:00"
generated_at: "2026-06-01T10:28:13.649922+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "low"
source: SEC EDGAR
---

# MEI Pharma presents voruciclib Phase 1b AML data at Brookline Symposium

## Summary
- CMO Richard Ghalie discussed voruciclib clinical data at virtual MDS/AML symposium on May 21, 2024.
- Voruciclib is an oral CDK inhibitor; ongoing Phase 1b in relapsed/refractory AML targeting resistance mechanisms.
- Specific efficacy/safety results are detailed in the attached corporate presentation (Exhibit 99.1) but not excerpted in the filing.

## SEC filing metadata
- accession: 0000950170-24-062739
- form_type: 8-K
- ticker: LITS
- cik: 0001262104
- company_name: Lite Strategy, Inc.
- filed_at: 2024-05-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1262104/000095017024062739/0000950170-24-062739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1262104/000095017024062739/meip-20240521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-062739
- JSON: https://secwatch.observer/filing/0000950170-24-062739.json
- Plain text: https://secwatch.observer/filing/0000950170-24-062739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.